Chiltern, a private equity firm, completed the investment in Centaur Healthcare, a contract development manufacturing organisation predominantly servicing the pharmaceutical market, with participation from Souter Investments and Bluester Capital. Financial terms were not disclosed. “Through our research and direct origination team, we had been targeting a platform investment in the pharmaceutical sector and Surepharm gives us a strong market entry point. We have built an ambitious management team of sector experts, and are looking forward to delivering the plan through a combination of organic investment and complementary M&A," Joe Bennett, Chiltern Capital Partner.